Prospective Trial Shows PAM50 Biomarker Predicts Hormone Therapy Benefit in Prostate Cancer
Study finds molecular signature identifies which men with recurrent disease respond to apalutamide plus salvage radiation therapy.
Copy and paste this URL into your WordPress site to embed
Copy and paste this code into your site to embed
